Leerink Partnrs Issues Optimistic Estimate for FDMT Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Research analysts at Leerink Partnrs boosted their FY2025 EPS estimates for 4D Molecular Therapeutics in a note issued to investors on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($3.69) for the year, up from their previous forecast of ($3.82). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics’ Q4 2025 earnings at ($0.81) EPS and FY2026 earnings at ($3.73) EPS.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative return on equity of 40.15% and a negative net margin of 594,375.81%.The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.52 million.

Other analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Roth Capital dropped their price target on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Finally, Chardan Capital restated a “buy” rating and set a $25.00 price target on shares of 4D Molecular Therapeutics in a research report on Tuesday, August 12th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $30.40.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $9.84 on Friday. The stock has a market cap of $459.53 million, a PE ratio of -2.79 and a beta of 2.93. The firm has a fifty day moving average price of $7.57 and a 200 day moving average price of $5.13. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $10.73.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its position in shares of 4D Molecular Therapeutics by 117.4% in the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the period. Assenagon Asset Management S.A. grew its position in shares of 4D Molecular Therapeutics by 2.3% in the third quarter. Assenagon Asset Management S.A. now owns 663,657 shares of the company’s stock valued at $5,767,000 after purchasing an additional 14,832 shares during the period. Rangeley Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics in the second quarter valued at about $48,000. Man Group plc grew its position in shares of 4D Molecular Therapeutics by 159.7% in the second quarter. Man Group plc now owns 134,932 shares of the company’s stock valued at $501,000 after purchasing an additional 82,980 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of 4D Molecular Therapeutics by 128.5% in the second quarter. BNP Paribas Financial Markets now owns 63,914 shares of the company’s stock valued at $237,000 after purchasing an additional 35,948 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.